Apogee Therapeutics, Inc. (APGE)
89.54
+6.82
(+8.24%)
USD |
NASDAQ |
Jun 11, 16:00
89.54
0.00 (0.00%)
After-Hours: 19:32
Apogee Therapeutics Shareholders Equity (Quarterly) : 1.256B for March 31, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 1.256B |
| December 31, 2025 | 903.88M |
| September 30, 2025 | 586.34M |
| June 30, 2025 | 619.40M |
| March 31, 2025 | 673.36M |
| December 31, 2024 | 716.79M |
| September 30, 2024 | 734.40M |
| Date | Value |
|---|---|
| June 30, 2024 | 773.64M |
| March 31, 2024 | 801.48M |
| December 31, 2023 | 379.91M |
| September 30, 2023 | 409.24M |
| June 30, 2023 | 113.05M |
| March 31, 2023 | 130.82M |
| December 31, 2022 | 142.08M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Evommune, Inc. | 304.56M |
| Cogent Biosciences, Inc. | 607.69M |
| Kymera Therapeutics, Inc. | 1.540B |
| Erasca, Inc. | 393.53M |
| GRAIL, Inc. | 2.501B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.294B |
| Total Liabilities (Quarterly) | 37.86M |
| Debt to Equity Ratio | 0.0064 |
| Current Ratio | 32.59 |
| Net Debt Paydown Yield | 0.01% |